
    
      This is an open-labeled, randomized clinical trial. After ICFs are signed, patients' medical
      history will be gained for checking if they are eligible for this study or not. And then, on
      Day -1, eligible ones will randomly be divide into two separate group: NALDEBAIN or MORPHINE.
      Group NALDEBAIN will receive Nadebain by gluteus maximus injection between 12 and 24 hours
      prior to surgery for postoperative pain relief. Group MORPHINE will receive morphine as
      needed after surgery. All necessary data will be gain form EMR or patient dairies.
    
  